These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38076758)

  • 1. Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
    Siontis KC; Abreau S; Attia ZI; Barrios JP; Dewland TA; Agarwal P; Balasubramanyam A; Li Y; Lester SJ; Masri A; Wang A; Sehnert AJ; Edelberg JM; Abraham TP; Friedman PA; Olgin JE; Noseworthy PA; Tison GH
    JACC Adv; 2023 Oct; 2(8):. PubMed ID: 38076758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter Evaluation of the Impact of Therapies on Deep Learning-based Electrocardiographic Hypertrophic Cardiomyopathy Markers.
    Dhingra LS; Sangha V; Aminorroaya A; Bryde R; Gaballa A; Ali AH; Mehra N; Krumholz HM; Sen S; Kramer CM; Martinez MW; Desai MY; Oikonomou EK; Khera R
    medRxiv; 2024 Mar; ():. PubMed ID: 38293023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
    Masri A; Lester SJ; Stendahl JC; Hegde SM; Sehnert AJ; Balaratnam G; Shah A; Fox S; Wang A
    J Am Heart Assoc; 2024 Apr; 13(8):e030607. PubMed ID: 38591260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
    Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.
    Yacoub MS; El-Nakhal T; Hasabo EA; Shehata N; Wilson K; Ismail KH; Bakr MS; Mohsen M; Mohamed A; Abdelazim E; Ali HT; Soliman Z; Sayed A; Abdelsayed K; Caliskan K; Soliman O
    Heart Fail Rev; 2024 Mar; 29(2):479-496. PubMed ID: 38112937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
    Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
    JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
    Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
    Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
    Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
    JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescents.
    Siontis KC; Liu K; Bos JM; Attia ZI; Cohen-Shelly M; Arruda-Olson AM; Zanjirani Farahani N; Friedman PA; Noseworthy PA; Ackerman MJ
    Int J Cardiol; 2021 Oct; 340():42-47. PubMed ID: 34419527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
    Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
    J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
    Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
    Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
    Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
    Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
    Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
    Tower-Rader A; Ramchand J; Nissen SE; Desai MY
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.